Abstract:Background: Mutations causing Parkinson's disease (PD) give diverse pathological phenotypes whose cellular correlates remain to be determined. For example, those with PRKN loss of function mutations have significantly earlier selective vulnerability of dopamine neurons, those with SNCA mutations have increased alpha-synuclein deposition, while those with LRRK2 mutations have additional deposition of tau. Yet all three mutation types are implicated in mitochondrial and/or lysosomal dysfunction. Direct comparison of cell models with these mutations would clarify the relative cellular dysfunctions associated with these different pathological phenotypes. Methods: An unbiased high-content imaging platform using orthogonal probes to assess both lysosomal and mitochondrial dysfunction, along with alpha-synuclein and tau protein deposition was established using induced pluripotent stem cell (iPSC) derived cortical and ventral midbrain neurons. Three mutation types, SNCA A53T, LRRK2 R1441G and PRKN loss of function (lof), were selected as exemplars of divergent PD pathological phenotypes and compared to each other, and to control iPSC from subjects without PD. Results: Different PD mutations caused cell type specific dysfunctions, likely to impact on both selective neuronal vulnerability and the pathologies observed in PD. Comparison of dopamine neurons identified that both lysosomal and mitochondrial dysfunction were predominant with PRKN lof mutations, whereas immunofluorescent staining revealed that SNCA A53T and LRRK2 R1441G mutations had increased tau deposition. In contrast, cortical neurons with SNCA and LRRK2 mutations both had mitochondrial and autophagy impairments without protein deposition, with LRRK2 cells additionally showing decreased glucocerebrosidase activity and increased alpha-synuclein phosphorylation. Conclusions: Lysosomal and mitochondrial dysfunction are predominant in dopamine neurons with PRKN lof mutations, and may drive the early selective loss of dopamine neurons in PRKN mutation carriers. More subtle cellular abnormalities in the SNCA A53T cell lines are likely to predispose to alpha-synuclein aggregation and tau protein deposition over time. The LRRK2 R1441G may also predispose to tau deposition, but despite substantial lysosomal dysfunction with increased alpha-synuclein phosphorylation, pathological alpha-synuclein accumulations were not observed. Understanding the mechanistic differences in how lysosomal and mitochondrial dysfunction impact on PD pathogenesis in different disease subtypes may be important for therapeutic development.

Robust In Vitro Models for Studying Parkinson's Disease? LUHMES Cells and SH-SH5Y Cells

Cell-based Assays for Parkinson's Disease Using Differentiated Human LUHMES Cells

The SH-SY5Y cell line in Parkinson’s disease research: a systematic review

Dopaminergic Neuron Asthe Cell Model for Parkinson's Disease

Human Midbrain Organoids: a Powerful Tool for Advanced Parkinson’s Disease Modeling and Therapy Exploration

Experimental models of Parkinson's disease: Challenges and Opportunities

Mimicking Parkinson’s Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models

Dopamine and cortical iPSC-derived neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction: implications for protein deposition versus selective cell loss

High-content phenotyping of Parkinson's disease patient stem cell-derived midbrain dopaminergic neurons using machine learning classification

Development of Midbrain Dopaminergic Neurons and the Advantage of Using hiPSCs as a Model System to Study Parkinson's Disease

iPSC modeling of young-onset Parkinson’s disease reveals a molecular signature of disease and novel therapeutic candidates

Developmental deficits and early signs of neurodegeneration revealed by PD patient derived dopamine neurons

In vitro modelling of Parkinson's disease using 6-OHDA is associated with increased NQO2 activity

Lipid levels correlate with neuronal and dopaminergic markers during the differentiation of SH-SY5Y cells

A review article on the development of dopaminergic neurons and establishment of dopaminergic neuron–based in vitro models by using immortal cell lines or stem cells to study and treat Parkinson's disease

Modeling Parkinson’s disease in midbrain-like organoids

Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation

Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson’s Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology

Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation

What we can learn from iPSC-derived cellular models of Parkinson's disease

Using induced pluripotent stem cells for modeling Parkinson's disease